Paclitaxel Through the Ages of Anticancer Therapy: Exploring Its Role in Chemoresistance and Radiation Therapy.
Paclitaxel Through the Ages of Anticancer Therapy: Exploring Its Role in Chemoresistance and Radiation Therapy.
复制标题
DOI：
10.3390/cancers7040897
复制
发表时间：
2015-12-03
期刊：
影响因子：
5.2
通讯作者：
Chen ZS
中科院分区：
文献类型：
--
作者：
Barbuti AM;Chen ZS
紫杉醇(Taxol®)是紫杉烷类抗癌药物的一员，也是治疗多种癌症最常用的化疗药物之一。紫杉醇是一种微管稳定剂，选择性地将细胞阻滞在细胞周期的G2/M期，并以时间和浓度依赖的方式诱导细胞毒性。由于紫杉醇的作用机制和辐射增敏作用，紫杉醇已被嵌入白蛋白和聚合物胶束纳米粒等新型药物制剂中，并应用于许多抗癌治疗方案。虽然紫杉醇是临床上使用多年的主要抗癌药物，但其治疗效果受到抗癌药物常见障碍的限制。这些障碍包括毒性、从头屈光和获得性多药耐药(MDR)。本文从紫杉醇的独特历史和药理入手，对紫杉醇的现状进行全面综述，探讨紫杉醇的耐药机制及其与放射治疗的联合作用，重点介绍紫杉醇目前的治疗方案、剂型和新发现。
Paclitaxel (Taxol®) is a member of the taxane class of anticancer drugs and one of the most common chemotherapeutic agents used against many forms of cancer. Paclitaxel is a microtubule-stabilizer that selectively arrests cells in the G2/M phase of the cell cycle, and found to induce cytotoxicity in a time and concentration-dependent manner. Paclitaxel has been embedded in novel drug formulations, including albumin and polymeric micelle nanoparticles, and applied to many anticancer treatment regimens due to its mechanism of action and radiation sensitizing effects. Though paclitaxel is a major anticancer drug which has been used for many years in clinical treatments, its therapeutic efficacy can be limited by common encumbrances faced by anticancer drugs. These encumbrances include toxicities, de novo refraction, and acquired multidrug resistance (MDR). This article will give a current and comprehensive review of paclitaxel, beginning with its unique history and pharmacology, explore its mechanisms of drug resistance and influence in combination with radiation therapy, while highlighting current treatment regimens, formulations, and new discoveries.